创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: Technical Advantages of PDC High-Throughput In Vitro Drug Efficacy Platform

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-04-03 13:30
  • Views:

(Summary description)In the field of drug discovery and development, how to accurately and efficiently assess the effects and safety of drugs has always been the goal of scientists. InnoModels' PDC high-throughput in vitro drug efficacy platform brings a new breakthrough in this field with its unique technology and advantages

InnoModels Biotechnology: Technical Advantages of PDC High-Throughput In Vitro Drug Efficacy Platform

(Summary description)In the field of drug discovery and development, how to accurately and efficiently assess the effects and safety of drugs has always been the goal of scientists. InnoModels' PDC high-throughput in vitro drug efficacy platform brings a new breakthrough in this field with its unique technology and advantages

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-04-03 13:30
  • Views:
Information

In the field of drug discovery and development, how to accurately and efficiently assess the effects and safety of drugs has always been the goal of scientists. InnoModels' PDC high-throughput in vitro drug efficacy platform brings a new breakthrough in this field with its unique technology and advantages.
1. Highly Consistent Primary Cells
Using the digestion products of PDX (patient-derived xenograft) models, the PDC high-throughput in vitro pharmacodynamic platform of InnoModels Biotechnology has successfully obtained primary cells that are highly consistent with patients. These primary cells not only have complex cell subpopulations, but also retain authentic biological characteristics, allowing the drug to act and respond more closely to the clinical situation. Compared with traditional cell lines, such highly consistent primary cells provide more accurate and reliable experimental data for drug development.
2、Efficient drug screening capability
The platform has a powerful high-throughput drug screening capability, which allows for rapid and accurate evaluation of a large number of drugs. By comparing the subject drug with counterpart drugs (e.g., drugs with similar mechanism of action or standardized therapeutic drugs), researchers can quickly screen out potential drug candidates and provide strong support for subsequent clinical trials.

 


3、Predicting the clinical effectiveness of drugs
In addition to drug screening, the platform can also predict the clinical effectiveness of drugs. By comparing the performance of the subject drug in in vitro experiments with the efficacy data of known drugs, researchers can initially determine the success rate of the drug in clinical trials. This prediction capability greatly shortens the drug development cycle, reduces R&D costs, and brings higher economic benefits to pharmaceutical companies.
4、Wide range of applications
InnoModels' PDC high-throughput in vitro drug efficacy platform is applicable to a wide range of drug development types, including antitumor drugs, antiviral drugs, and neurological drugs. In addition, the platform can also be used to evaluate drug resistance and safety, providing comprehensive technical support for drug development.
5. Conclusion
To summarize, the PDC high-throughput in vitro drug efficacy platform of InnoModels Biotechnology has brought significant technological innovation to the field of drug discovery and development with its high consistency of primary cells, highly efficient drug screening capability, predictive drug clinical efficacy, and wide range of applications. With the continuous optimization and improvement of the platform, it is believed that it will bring more innovations to pharmaceutical companies and research institutes, and promote the continuous development of the drug R&D field.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司